糖尿病合并冠心病患者中Amphilimus与佐他莫司洗脱支架比较:SUGAR试验
SUGAR试验为西班牙23中心随机对照研究,纳入1175例需行PCI的糖尿病患者,1:1比较Cre8 EVO(西罗莫司两亲性载体)与Resolute Onyx(佐他莫司聚合物)支架。1年靶病变失败率Cre8 EVO组7.2%、Resolute Onyx组10.9%(HR 0.65,95%CI 0.44-0.96;非劣效P<0.001,优效P=0.030)。
要点
- 糖尿病PCI患者中,Cre8 EVO支架1年靶病变失败非劣于Resolute Onyx支架。
- 预设优效性探索分析显示Cre8 EVO方案可能优于Resolute Onyx(HR 0.65)。
- 两组支架内血栓及全因死亡无显著差异。
核心结论
- 在糖尿病患者中,Cre8 EVO支架1年靶病变失败复合终点非劣于Resolute Onyx支架。
- 1年优效性探索分析提示Cre8 EVO支架在同一终点上可能优于Resolute Onyx支架。
研究设计与样本
- 研究者发起的随机对照、评估者盲法试验,西班牙23个中心开展。
- 纳入需行经皮冠状动脉介入治疗的糖尿病患者1175例,1:1随机分配至Cre8 EVO或Resolute Onyx支架。
- 主要终点为1年靶病变失败,定义为心源性死亡、靶血管心肌梗死和临床指征靶病变血运重建的复合终点。
- 非劣效设计,主要终点界值4%;若确认非劣效则进行优效性分析。
主要发现
- 主要终点事件共106例:Cre8 EVO组42例(7.2%),Resolute Onyx组64例(10.9%)(HR 0.65,95%CI 0.44-0.96;非劣效P<0.001;优效P=0.030)。
- 靶血管失败:Cre8 EVO组7.5% vs Resolute Onyx组11.1%(HR 0.67,95%CI 0.46-0.99;P=0.042)。
- 可能的或确定的支架内血栓及全因死亡在两组间无显著差异。
临床怎么用
- 对于合并糖尿病的冠心病PCI患者,可考虑选用Cre8 EVO支架以降低1年靶病变失败风险。
- 支架选择需结合患者个体情况与术者判断,本试验支持Cre8 EVO在该人群中的非劣效性及探索性优效信号。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: Patients with diabetes mellitus are at high risk of adverse events after percutaneous revascularization, with no differences in outcomes between most contemporary drug-eluting stents. The Cre8 EVO stent releases a formulation of sirolimus with an amphiphilic carrier from laser-dug wells, and has shown clinical benefits in diabetes. We aimed to compare Cre8 EVO stents to Resolute Onyx stents (a contemporary polymer-based zotarolimus-eluting stent) in patients with diabetes. METHODS AND RESULTS: We did an investigator-initiated, randomized, controlled, assessor-blinded trial at 23 sites in Spain. Eligible patients had diabetes and required percutaneous coronary intervention. A total of 1175 patients were randomly assigned (1:1) to receive Cre8 EVO or Resolute Onyx stents. The primary endpoint was target-lesion failure, defined as a composite of cardiac death, target-vessel myocardial infarction, and clinically indicated target-lesion revascularization at 1-year follow-up. The trial had a non-inferiority design with a 4% margin for the primary endpoint. A superiority analysis was planned if non-inferiority was confirmed. There were 106 primary events, 42 (7.2%) in the Cre8 EVO group and 64 (10.9%) in the Resolute Onyx group [hazard ratio (HR): 0.65, 95% confidence interval (CI): 0.44-0.96; Pnon-inferiority < 0.001; Psuperiority = 0.030]. Among the secondary endpoints, Cre8 EVO stents had significantly lower rate than Resolute Onyx stents of target-vessel failure (7.5% vs. 11.1%, HR: 0.67, 95% CI: 0.46-0.99; P = 0.042). Probable or definite stent thrombosis and all-cause death were not significantly different between groups. CONCLUSION: In patients with diabetes, Cre8 EVO stents were non-inferior to Resolute Onyx stents with regard to target-lesion failure composite outcome. An exploratory analysis for superiority at 1 year suggests that the Cre8 EVO stents might be superior to Resolute Onyx stents with regard to the same outcome. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov: NCT03321032.
引用
- Romaguera R, Salinas P, Gomez-Lara J, et al. Amphilimus- vs. zotarolimus-eluting stents in patients with diabetes mellitus and coronary artery disease: the SUGAR trial. Eur Heart J. 2022. PMID: 34735004. doi:10.1093/eurheartj/ehab790
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。